Delivra Health Brands Inc.
E-Commerce Growth Offsets Q2 Weakness, Market Missing the Upside Potential
Published: Mar 12, 2026
Author: FRC Analysts
Disclosure: Delivra Health Brands Inc. has paid FRC a fee for research coverage and distribution of reports. See last page for other important disclosures, rating, and risk definitions.
Company Details
Sector – Healthcare
Industry – Drug Manufacturers-Specialty & Generic
Trading Information
Trading information – DHB.V : SXV
Report Highlights
- Revenue Weakness Offset by E-Commerce Growth: Q2 (ended December 2025) revenue fell 12% YoY, and came in 14% below our estimate, mainly due to weaker Canadian sales (down 35% YoY), driven by the timing of large customer orders. Historically, Q2 revenue has been uneven, driven not only by order timing and distributor shipments, but also by the holiday season. Positively, YTD direct-to-consumer e-commerce sales grew 27% YoY, reflecting strong customer engagement, and repeat purchases.
- EBITDA Impacted by Margin Pressure: EBITDA declined due to lower revenue, and gross margins. Although EPS improved YoY, from ($0.03) to ($0.01), due to lower depreciation expenses, it still fell short of our forecasted modest profit of $0.001/share. The narrow loss suggests the business remains near profitability, and could scale rapidly with top-line growth.
- Undervalued Balance Sheet: Working capital minus long-term debt is $4M vs a $5M MCAP, implying the market values the operating business at ~$1M. DHB trades at 0.31x forward revenue vs a 1.03x average for comparables, a 69% discount. We believe this suggests meaningful upside potential if investors value the company’s strong cash position, and growth potential.
- Stock Performance Relative to Sector: DHB’s shares are up 10% YoY, outperforming the S&P Personal Care Index (down 9% YoY), which faced soft demand from inflation-weary consumers, and margin pressure from higher input costs. Our 2026 outlook is cautiously positive, with stabilizing input costs, and improving affordability from lower interest rates.
- 2026 Outlook & Product Expansion: Following Q2 weakness, we anticipate a full-year revenue pullback, the first after five consecutive years of growth (FY2021–22: 2%, FY2023: 20%, FY2024: 26%, FY2025: 8%). Long-term fundamentals remain strong due to rising consumer awareness of sleep health. DHB plans to launch two to three new products soon, and revamp LivRelief Infused sales through a new distributor.
- Strategic M&A Opportunities: DHB aims to expand its product portfolio via M&A. Strong distribution channels should allow acquired products to quickly reach retail shelves.
Price and Volume (1-year)
* Delivra Health has paid FRC a fee for research coverage and distribution of reports. All figures in C$ unless otherwise specified. See last page for other important disclosures, rating, and risk definitions.
Overview
Products
Click on the button above to view the complete report
The opinions expressed in this report are the true opinions of the analyst(s) about any companies and industries mentioned. Any “forward looking statements” are our best estimates and opinions based upon information that is publicly available and that we believe to be correct, but we have not independently verified with respect to truth or correctness. There is no guarantee that our forecasts will materialize. Actual results will likely vary. The companies listed above are covered by FRC under an issuer-paid model, where fees have been paid to FRC to commission this report and research coverage. This creates a potential conflict of interest which readers should consider. Distribution procedure: our reports are distributed first to our web-based subscribers on the date shown on this report then made available to delayed access users through various other channels for a limited time. To subscribe for real-time access to research, visit https://www.researchfrc.com/plans for subscription options. This report contains “forward looking” statements. Forward-looking statements regarding the Company, industry, and/or stock’s performance inherently involve risks and uncertainties that could cause actual results to differ from such forward-looking statements. Factors that would cause or contribute to such differences include, but are not limited to, continued acceptance of the Company’s products/services in the marketplace; acceptance in the marketplace of the Company’s new product lines/services; competitive factors; new product/service introductions by others; technological changes; dependence on suppliers; systematic market risks and other risks discussed in the Company’s periodic report filings, including interim reports, annual reports, and annual information forms filed with the various securities regulators. By making these forward-looking statements, Fundamental Research Corp. and the analyst/author of this report undertakes no obligation to update these statements for revisions or changes after the date of this report. Fundamental Research Corp DOES NOT MAKE ANY WARRANTIES, EXPRESSED OR IMPLIED, AS TO RESULTS TO BE OBTAINED FROM USING THIS INFORMATION AND MAKES NO EXPRESS OR IMPLIED WARRANTIES OR FITNESS FOR A PARTICULAR USE. ANYONE USING THIS REPORT ASSUMES FULL RESPONSIBILITY FOR WHATEVER RESULTS THEY OBTAIN FROM WHATEVER USE THE INFORMATION WAS PUT TO. ALWAYS TALK TO YOUR FINANCIAL ADVISOR BEFORE YOU INVEST. WHETHER A STOCK SHOULD BE INCLUDED IN A PORTFOLIO DEPENDS ON ONE’S RISK TOLERANCE, OBJECTIVES, SITUATION, RETURN ON OTHER ASSETS, ETC. ONLY YOUR INVESTMENT ADVISOR WHO KNOWS YOUR UNIQUE CIRCUMSTANCES CAN MAKE A PROPER RECOMMENDATION AS TO THE MERIT OF ANY PARTICULAR SECURITY FOR INCLUSION IN YOUR PORTFOLIO. This REPORT is solely for informative purposes and is not a solicitation or an offer to buy or sell any security. It is not intended as being a complete description of the company, industry, securities or developments referred to in the material. Any forecasts contained in this report were independently prepared unless otherwise stated, and HAVE NOT BEEN endorsed by the Management of the company which is the subject of this report. Additional information is available upon request. THIS REPORT IS COPYRIGHT. YOU MAY NOT REDISTRIBUTE THIS REPORT WITHOUT OUR PERMISSION. Please give proper credit, including citing Fundamental Research Corp and/or the analyst, when quoting information from this report. The information contained in this report is intended to be viewed only in jurisdictions where it may be legally viewed and is not intended for use by any person or entity in any jurisdiction where such use would be contrary to local regulations or which would require any registration requirement within such jurisdiction.
